Yoshida, Shigeo
Murakami, Tomoaki
Nozaki, Miho
Suzuma, Kiyoshi
Baba, Takayuki
Hirano, Takao
Sawada, Osamu
Sugimoto, Masahiko
Takamura, Yoshihiro
Tsuiki, Eiko
Funding for this research was provided by:
Bayer Yakuhin, Ltd.
Article History
Received: 25 May 2020
Revised: 3 September 2020
Accepted: 10 September 2020
First Online: 30 September 2020
Compliance with ethical standards
:
: Shigeo Yoshida has received a speaker honorarium from Bayer Yakuhin, Ltd., Novartis Pharma K.K., and Santen Pharmaceutical Co., Ltd. and has received subsidy and donation from Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co. Tomoaki Murakami has received a speaker honorarium from Bayer Yakuhin, Ltd., and Novartis Pharma K.K. and has received research funds from Novartis Pharma K.K. Miho Nozaki has received a speaker honorarium from Novartis Pharma K.K. Takao Hirano has received a speaker honorarium from Novartis Pharma K.K. Masahiko Sugimoto has received a research funds from Alcon Japan Ltd., and Bayer Yakuhin, Ltd. and has received speaker honorarium and consulting fees from Alcon Japan Ltd., Kowa Company, Ltd., Senju Pharmaceutical Co., Ltd., Daiichi Yakuhin Sangyo Co., Ltd., Bayer Yakuhin, Ltd., and Wakamoto Pharmaceutical Co., Ltd.Interscience Co., Ltd. assisted in the writing and editing of this paper with funding from Bayer Yakuhin, Ltd. All authors wrote this review considering the view of expert doctors with the assistance of Interscience Co., Ltd.; however, Bayer Yakuhin, Ltd. has not been involved in the preparation of this article in any way.
: This article does not contain any studies with human participants or animals performed by any of the authors.